Status:
RECRUITING
Skeletal Muscle Function in Interstitial Lung Disease
Lead Sponsor:
University of British Columbia
Conditions:
Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may...
Detailed Description
PURPOSE: The primary purpose of the proposed work is to characterize skeletal muscle function in patients with interstitial lung disease (ILD), and to determine the physiological and sensory conseque...
Eligibility Criteria
Inclusion
- Inclusion Criteria for ILD Patients:
- Age 40-80 years (inclusive)
- A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses
- Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis
- Appropriate candidate for pulmonary rehabilitation
- 6 minute walk distance 50m or more
- Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air
- Clinically stable for the preceding 6 weeks
- Can fluently read and write in English
- Inclusion Criteria for Healthy Controls:
- Age 40-80 (inclusive)
- Normal pulmonary function (80-120% predicted)
- No lung or cardiovascular disease
- Can fluently read and write in English
- Exclusion Criteria for the ILD patients:
- Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)
- Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation
- Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%
- Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program
- Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit
- Significant emphysema (less than 10% volume on HRCT or FEV1/FVC less than 0.70)
- Exclusion Criteria for Healthy Controls:
- Currently smoking or previously smoked more than 10 pack-years
- Any medical conditions that prevents them for exercising safely
- Cardiac pacemaker or any metal or electronic inside the body
Exclusion
Key Trial Info
Start Date :
August 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03800017
Start Date
August 7 2024
End Date
December 31 2026
Last Update
January 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Paul's Hospital
Vancouver, British Columbia, Canada, V6Z1Y6